Investing Profile

Steven Gillis

InvestorVC
Managing Director at ARCH Venture Partners
Photo of Steven Gillis, Managing Director at ARCH Venture Partners
cb
ARCH Venture Partners Managing Director
$50K - $150.0M
$25.0M
40
$635.8M
CompanyStageDateRound SizeTotal Raised
Be Biopharma
Series UnknownOct 2024$82M
Series BApr 2022$130M
$260M
Co-investors: Robert Nelsen (ARCH Venture Partners), Jason Rhodes (Atlas Venture)
EGenesis
Series DSep 2024$190M
Series CMar 2021$130M
Series BNov 2019$100M
Series AMar 2017$38M
$450M
Co-investors: Peter Hebert (Lux Capital), Isaac Ciechanover (Polaris Partners), Lucio Iannone (Leaps by Bayer), Boris Nikolic (Biomatics Capital Partners)
Vilya
Series AJun 2024$21M
Series AAug 2022$50M
$71M
Co-investors: Greg Yap (Menlo Ventures), Robert Nelsen (ARCH Venture Partners)
Proniras
Series BFeb 2024$5M
$5M
Basking Biosciences
Series AJan 2024$55M
$55M
TFC Therapeutics
Pre SeedAug 2023
Co-investors: Ludwig Schulze (Alumni Ventures )
Bitterroot Bio
Series AJun 2023$150M
$150M
Co-investors: Anthony Philippakis (GV (Google Ventures)), Andrew ElBardissi (Deerfield Management)
SonoThera
Series ADec 2022$61M
$61M
Co-investors: Tom Willis (Illumina Ventures), Brian Halak (Domain Associates), Asish Xavier (Johnson & Johnson Innovation), Lu Wang (Foothill Ventures (formerly Tsingyuan Ventures)), Lori Hu (Vertex Ventures)